Aug. 25 at 2:11 AM
$BMEA Today’s volume (7.9M vs 548K avg, ~14x) and the price action got the board pretty excited. Understandable — that’s a real move for this name.
But worth keeping perspective here. Today’s catalyst was the COVALENT-211 enrollment completion — a diabetes trial milestone, not the BMF-650 readout. The real event hasn’t happened yet.
On BMF-650 specifically: 3-5% placebo-adjusted weight loss at Day 28 would already be a meaningful result for an oral GLP-1 this early. Anything meaningfully above that is gravy. No need to anchor on best-case numbers before the data even prints.
Whatever today was — short covering, thin float, analyst notes stacking up (Citi, Piper Sandler, Oppenheimer) — it’s not the main event. Save the ammo. The real catalyst is still ahead.
